COST-EFFECTIVENESS OF OFATUMUMAB COMPARED WITH OTHER DISEASE-MODIFYING THERAPIES FOR THE TREATMENT OF RELAPSING MULTIPLE SCLEROSIS IN GREECE

被引：0
|
作者：
Petropoulos, A. [1 ]
Cooney, P. [2 ]
Patidar, M. [3 ]
Gudala, K. [3 ]
Tiwari, S. [4 ]
Brennan, R. [2 ]
Kapsogeorgiou, K. [1 ]
Cheilas, G. [1 ]
Banhazi, J. [5 ]
机构：
[1] Novartis Hellas SACI, Athens A1, Greece
[2] Novartis Ireland Ltd, Dublin, Ireland
[3] Novartis Healthcare Private Ltd, Hyderabad, India
[4] Novartis Healthcare Private Ltd, Hyderabad, Andhra Pradesh, India
[5] Novartis Pharma AG, Basel, BS, Switzerland
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE143
引用
收藏
页码：S80 / S81
页数：2
相关论文
共 50 条
  • [31] Stick or twist? Cost-effectiveness of siponimod compared with continuing existing disease-modifying therapies in the treatment of active secondary progressive multiple sclerosis in the UK
    Montgomery, S.
    Woodhouse, F.
    Vudumula, U.
    Gudala, K.
    Duddy, M.
    Kroes, M.
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 669 - 678
  • [32] The Shifting Landscape of Disease-Modifying Therapies for Relapsing Multiple Sclerosis
    Burton, Jodie M.
    Freedman, Mark S.
    JOURNAL OF NEURO-OPHTHALMOLOGY, 2018, 38 (02) : 210 - 216
  • [33] Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis
    Hernandez, Luis
    Guo, Shien
    Toro-Diaz, Hector
    Carroll, Stuart
    Farooq, Syed Feisal Syed
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (03) : 228 - 238
  • [34] Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada
    Moogeh Baharnoori
    Virender Bhan
    Fraser Clift
    Kimberly Thomas
    Soukaïna Mouallif
    Nicholas Adlard
    Philip Cooney
    François Blanchette
    Barkha P. Patel
    Daniel Grima
    PharmacoEconomics - Open, 2022, 6 : 859 - 870
  • [35] Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada
    Baharnoori, Moogeh
    Bhan, Virender
    Clift, Fraser
    Thomas, Kimberly
    Mouallif, Soukaina
    Adlard, Nicholas
    Cooney, Philip
    Blanchette, Francois
    Patel, Barkha P.
    Grima, Daniel
    PHARMACOECONOMICS-OPEN, 2022, 6 (06) : 859 - 870
  • [36] Disease modifying therapies in multiple sclerosis: cost-effectiveness systematic review
    Eduardo Navarro, Cristian
    Ordonez-Callamand, Eliana
    Pablo Alzate, Juan
    FARMACIA HOSPITALARIA, 2020, 44 (02) : 68 - 76
  • [37] Cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing–remitting multiple sclerosis: a systematic review
    Nasrin Abulhasanbeigi Gallehzan
    Majid Khosravi
    Khosro Jamebozorgi
    Nazanin Mir
    Habib Jalilian
    Samira Soleimanpour
    Saeed Hoseini
    Aziz Rezapour
    Abbas Eshraghi
    Health Economics Review, 14
  • [38] Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom
    Timothy Spelman
    William L. Herring
    Yuanhui Zhang
    Michael Tempest
    Isobel Pearson
    Ulrich Freudensprung
    Carlos Acosta
    Thibaut Dort
    Robert Hyde
    Eva Havrdova
    Dana Horakova
    Maria Trojano
    Giovanna De Luca
    Alessandra Lugaresi
    Guillermo Izquierdo
    Pierre Grammond
    Pierre Duquette
    Raed Alroughani
    Eugenio Pucci
    Franco Granella
    Jeannette Lechner-Scott
    Patrizia Sola
    Diana Ferraro
    Francois Grand’Maison
    Murat Terzi
    Csilla Rozsa
    Cavit Boz
    Raymond Hupperts
    Vincent Van Pesch
    Celia Oreja-Guevara
    Anneke van der Walt
    Vilija G. Jokubaitis
    Tomas Kalincik
    Helmut Butzkueven
    PharmacoEconomics, 2022, 40 : 323 - 339
  • [39] Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom
    Spelman, Timothy
    Herring, William L.
    Zhang, Yuanhui
    Tempest, Michael
    Pearson, Isobel
    Freudensprung, Ulrich
    Acosta, Carlos
    Dort, Thibaut
    Hyde, Robert
    Havrdova, Eva
    Horakova, Dana
    Trojano, Maria
    De Luca, Giovanna
    Lugaresi, Alessandra
    Izquierdo, Guillermo
    Grammond, Pierre
    Duquette, Pierre
    Alroughani, Raed
    Pucci, Eugenio
    Granella, Franco
    Lechner-Scott, Jeannette
    Sola, Patrizia
    Ferraro, Diana
    Grand'Maison, Francois
    Terzi, Murat
    Rozsa, Csilla
    Boz, Cavit
    Hupperts, Raymond
    Van Pesch, Vincent
    Oreja-Guevara, Celia
    van der Walt, Anneke
    Jokubaitis, Vilija G.
    Kalincik, Tomas
    Butzkueven, Helmut
    PHARMACOECONOMICS, 2022, 40 (03) : 323 - 339
  • [40] The Cost of Multiple Sclerosis and the Cost Effectiveness of Disease-Modifying Agents in its Treatment
    Ceri J. Phillips
    CNS Drugs, 2004, 18 : 561 - 574
12345